TrialInvestigational new drugs2015

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.

David Schiff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.